Lumexa Imaging (NASDAQ:LMRI) has received a significant upgrade from Raymond James Financial, moving from an “outperform” rating to a “strong-buy” rating, according to a research note released to investors on Monday. The brokerage has set a price target of $23.00 for the stock, indicating a potential upside of 112.96% from its current trading price.
As of Monday, Lumexa Imaging’s shares opened at $10.80, reflecting a 6.5% increase. The stock has experienced fluctuations over the past year, with a twelve-month low of $9.97 and a high of $19.45.
Institutional Investment Insights
Recent trading activity reveals growing institutional interest in Lumexa Imaging. Notably, Assetmark Inc. has acquired a new position in the company during the fourth quarter. This acquisition involved purchasing 1,957 shares of Lumexa Imaging, valued at approximately $36,000, as disclosed to the Securities and Exchange Commission.
The increasing institutional investment underscores confidence in Lumexa Imaging’s market potential. The company is recognized as one of the largest national providers of diagnostic imaging services in the United States.
About Lumexa Imaging
With a robust platform that is both integrated and scalable, Lumexa Imaging has established a proven track record in creating value for its stakeholders. As of September 30, 2025, Lumexa Imaging and its affiliates operated the second-largest outpatient imaging center network in the United States, comprising 184 centers across 13 states. The company also maintains eight joint venture partnerships with various health systems, strategically positioning its centers in attractive metropolitan statistical areas.
As the demand for diagnostic imaging services continues to grow, Lumexa Imaging’s recent rating upgrade by Raymond James Financial could be a pivotal moment for investors looking to capitalize on the company’s upward trajectory.
